Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles
NCT ID: NCT01791751
Last Updated: 2013-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
10 participants
INTERVENTIONAL
2012-06-30
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles
NCT01037699
Clomifene Citrate as First Line Treatment in in Vitro Fertilization Cycles for Patients With Lower Ovarian Reserve
NCT01389713
Comparison of Clomiphene Citrate and Gonadotropins in Ovulation Induction Cycles
NCT00835744
Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF
NCT02201914
Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation
NCT00633347
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clomifene Citrate
Clomifene Citrate 50 mg
Clomifene Citrate
Clomiphene citrate 100 mg daily for 5 days
Control
No intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clomifene Citrate
Clomiphene citrate 100 mg daily for 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-35 years old
* BMI 18-29 Kg/m2
* Normal basal hormonal levels
* No contraceptive pill
Exclusion Criteria
* Previous participation in the study
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundació Privada Eugin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marta Colodron, MD
Role: PRINCIPAL_INVESTIGATOR
Clinica EUGIN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clínica EUGIN
Barcelona, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-002173-33
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CLOFA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.